Prognostic significance of lymphocyte reconstitution in the early phase after cord blood transplantation

Abstract

1. Barlogie B. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24(6):929–36. 2. Sobh M, Michallet M, Gahrton G, Iacobelli S, Van Biezen A, Sch€ onland S, et al. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: Trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016;30 (10):2047–54. 3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20. 4. Davies JK, Taussig D, Oakervee H, Smith M, Agrawal S, Cavenagh JD, et al. Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using nonmyeloablative conditioning without T cell depletion. Br J Haematol. 2013;162(4):525–9. 5. Savoie ML, Davies JK, Jamie C, Oakervee H, Jonathan S, Matthew S, et al. P001 Low treatment related mortality and relapse leading to excellent outcomes after allogeneic transplantation for acute lymphoblastic leukaemia using a non-myeloablative conditioning without T CELL depletion – Poster Session. Bone Marrow Transplant. 2019;54(1):144–619. 6. Auer RL, MacDougall F, Oakervee HE, Taussig D, Davies JK, Syndercombe-Court D, et al. T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies. Br J Haematol. 2012;157(5):580–5. 7. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106(9):2969–76. 8. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110–20. 9. Gahrton G, Iacobelli S, Bj€ orkstrand B, Bj€ orkstrand B, Hegenbart U, Gruber A, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055–63. 10. Knop S, Engelhardt M, Liebisch P, Meisner C, Holler E, Metzner B, et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia. 2019;33(11):2710–9. 11. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474–80. 12. Rosi~ nol L, P erez-Sim on JA, Sureda A, De La Rubia J, De Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591–3. 13. Krishnan A. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195–203. 14. Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten M-J, van Oers M, Raymakers R, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219–25. 15. Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, et al. Allogeneic transplantation of multiple myeloma patients may allow longterm survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019;104(2):370–9. 16. Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, et al. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica. 2019;104(2):380–91.